IPH Limited (IPH) Earnings Call Transcripts

IPH Limited's Latest Earnings Call - March 26, 2026

Innate Pharma S.A. reported its Full Year 2025 results on March 26, 2026, with total revenue of EUR 9 million, reflecting a decrease from the previous year. The company is focusing on three key clinical assets: lacutamab, IPH4502, and monalizumab, with significant upcoming milestones expected in the second half of 2026. Management emphasized a disciplined approach to capital allocation and strategic partnerships to support late-stage development, while maintaining a cash position of EUR 44.8 million, providing funding visibility until Q3 2026.

Reported metrics

Guidance from management

Management maintained guidance for continued focus on key clinical assets and emphasized the importance of strategic partnerships to support late-stage development. They expect to initiate the TELLOMAK-3 trial in the second half of 2026.

What management said

Sure. We have established the MTD, and this is going to be, let's say, at an expected level according to what we know for other exatecan-based assets. And it is very encouraging to see this preliminary activity at the therapeutic dose in different tumor types. And we are going to eventually explore even further this clinical activity.

With regards to the revenue, you have to be careful because, in fact, it relates to the old agreement where we were co-developing the early stage of development. So this is the very leftover, and those projects are over. So now the project is completely in the end of AstraZeneca. So the accounting treatment is slightly different. It's not going through the revenue, it's through collaboration liabilities of the balanc...

What analysts pressed on

Analysts expressed concerns regarding the drop in collaboration revenue for monalizumab and the need for clarity on future milestone payments. There were also questions about the competitive landscape for IPH4502 and the potential for additional data readouts in the near term.

Main topics on the call

• Focus on Key Clinical Assets — Management reiterated their commitment to advancing three high-value programs: lacutamab, IPH4502, and monalizumab. CEO Jonathan Dickinson stated, "we remain focused on advancing our pipeline and delivering on these upco...
• Lacutamab Phase III Trial Initiation — Innate received FDA clearance to proceed with the TELLOMAK-3 Phase III trial for lacutamab, expected to initiate in the second half of 2026. This trial is crucial for potential accelerated approval in cutaneous T-cell ly...
• Progress of IPH4502 — IPH4502 is showing early signs of antitumor activity in heavily pretreated patients, with a favorable safety profile. Management noted, "we are starting to validate our preclinical hypothesis," indicating confidence in t...
• Monalizumab Trial Updates — The PACIFIC-9 Phase III trial for monalizumab has completed enrollment, with data expected in the second half of 2026. This trial is pivotal for assessing the drug's efficacy in non-small cell lung cancer.

Read the full IPH Limited transcript (March 26, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 52 IPH Limited earnings call transcripts on record, spanning February 12, 2020 to August 20, 2026. Based on this history, IPH Limited reports quarterly. The most recent call on file is dated August 20, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IPH

Exchange

ASX

Country

AU

Sector

Industrials

Industry

Professional Services

Calls on record

52

First call

February 12, 2020

Most recent

August 20, 2026

Reporting cadence

quarterly